Burning Rock Biotech Ltd is a diagnostics & research business based in the US. Burning Rock Biotech Ltd shares (BNR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.93 – a decrease of 10.81% over the previous week. Burning Rock Biotech Ltd employs 786 staff and has a trailing 12-month revenue of around $509.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.93 |
|---|---|
| 52-week range | $2.62 - $11.40 |
| 50-day moving average | $4.66 |
| 200-day moving average | $6.97 |
| Wall St. target price | $4.03 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-7.83 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.89 from 2024-10-15
| 1 week (2024-10-10) | -12.02% |
|---|---|
| 1 month (2024-09-17) | -13.73% |
| 3 months (2024-07-17) | -55.74% |
| 6 months (2024-04-17) | 261.25% |
| 1 year (2023-10-17) | 165.14% |
|---|---|
| 2 years (2022-10-17) | 31.36% |
| 3 years (2021-10-15) | 14.36 |
| 5 years (2019-10-13) | N/A |
| Revenue TTM | $509.8 million |
|---|---|
| Gross profit TTM | $380 million |
| Return on assets TTM | -30.91% |
| Return on equity TTM | -68.89% |
| Profit margin | -111.18% |
| Book value | $66.07 |
| Market Capitalization | $29.6 million |
TTM: trailing 12 months
We're not expecting Burning Rock Biotech Ltd to pay a dividend over the next 12 months.
Burning Rock Biotech Ltd's shares were split on a 1:10 basis on 14 May 2024. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Burning Rock Biotech Ltd shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Burning Rock Biotech Ltd shares which in turn could have impacted Burning Rock Biotech Ltd's share price.
Over the last 12 months, Burning Rock Biotech Ltd's shares have ranged in value from as little as $2.62 up to $11.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Burning Rock Biotech Ltd's is 0.131. This would suggest that Burning Rock Biotech Ltd's shares are less volatile than average (for this exchange).
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.